Fundraising Fox
Nuvaira
Minneapolis, US · Founded 2008 · Delaware corporation · 19 employees on LinkedIn · 9 known investors
Find your way into Nuvaira
Sign up to see every warm intro you have to Nuvaira
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuvaira team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD). The treatment targets COPD patients with lung hyperinflation and low emphysema, aiming to preserve lung function, reduce breathlessness, and lower exacerbations.
Founders & leadership
Nuvaira was founded in 2008 by Martin Mayse and Steve Dimmer.
MM
Martin MayseFounderMartin Mayse is a co-founder of Nuvaira and a board-certified physician in internal medicine and pulmonary medicine with fellowship training in interventional pulmonology.
DW
Dennis WahrPresident & CEODennis Wahr is a physician and medical device entrepreneur who previously co-founded and led Lutonix (acquired by CR Bard in 2011) and Velocimed (acquired by St. Jude Medical in 2005), and trained as an interventional cardiologist before transitioning to entrepreneurship and venture investing.
LF
Lisa FlahertyChief Strategy OfficerChief Strategy Officer at Nuvaira, Lisa Flaherty brings 25 years of medical device experience spanning clinical program development, market development, and commercial strategy. Her background includes transitioning medical technologies from clinical research to standards of care.
SS
Steve SathreVice President of FinanceVice President of Finance at Nuvaira, Steve Sathre has held roles in Big 4 accounting, private growth-stage companies, and publicly traded corporations.
SP
Steve PaidoshVice President of Operations
DW
Dennis Wahr M.D.CEODennis Wahr is an interventional cardiologist who co-founded Velocimed (acquired by St. Jude Medical in 2005) and Lutonix (acquired by CR Bard in 2011), serving as President and CEO of each. He joined Nuvaira as President and CEO in 2012 and has held board positions at multiple medical device companies including Accumetrics, IDev, and Intact Vascular.
Board
GD
Geoffrey DuykBoard director
DS
Doug SissonBoard director
KN
Kirk NielsenBoard director
DS
Dave StassenBoard director
MD
Investors · 9
Windham Capital Partnerslisted by Windham Capital PartnersNew York · $1M – $5M
How we know: press coverage · Not right? Tell us
Endeavour VisionreportedGeneva
How we know: press coverage · Not right? Tell us
Lightstone VenturesreportedPortola Valleyvia Mike Carusi · board
How we know: a partner's Signal profile · board seat on SEC Form D · press coverage · Not right? Tell us
MorgenthalerreportedPortola Valley
How we know: a partner's Signal profile · Not right? Tell us
Qiming Venture PartnersreportedBeijingvia Gary Rieschel · board
How we know: board seat on SEC Form D · press coverage · Not right? Tell us
Richard King Mellon Foundationreported
How we know: press coverage · Not right? Tell us
Split Rock PartnersreportedEden Prairie · $2M – $40M
How we know: board seat on SEC Form D · press coverage · Not right? Tell us
U.S. Venture PartnersreportedMinneapolis
How we know: press coverage · Not right? Tell us
Versant VenturesreportedSan Francisco · $250K – $5M
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$154.3M disclosed across 8 rounds · 2014–2026
▶$35.8MraisedMar 2026 · 9 investors · Other Health CareRule 506(b)
▶$35.8MraisedMar 2026 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward J. MorganDirector
- Geoffrey DuykDirector
- Timothy HerbertDirector
- Dennis W. WahrExecutive Officer, Director
- Offering amount
- $63.6M
- Amount sold
- $35.8M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$979.2KraisedAug 2025 · 8 investors · Other Health CareRule 506(b)
▶$979.2KraisedAug 2025 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey DuykDirector
- Doug SissonDirector
- Timothy HerbertDirector
- Dennis W. WahrExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $979.2K
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$52.9KraisedMay 2024 · 13 investors · Other Health Care
▶$52.9KraisedMay 2024 · 13 investors · Other Health Care
Officers, directors & promoters on the filing
- Jonathan RootDirector
- Timothy HerbertDirector
- Henry PlainDirector
- Dennis W. WahrExecutive Officer, Director
- David Van MeterDirector
- Jaques EssingerDirector
- Tom GriffinExecutive Officer
- Michael A. CarusiDirector
- Offering amount
- $56.4K
- Amount sold
- $52.9K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04
▶$15.1MraisedDec 2023 · 39 investors · Other Health CareRule 506(b)
▶$15.1MraisedDec 2023 · 39 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David Van MeterDirector
- Timothy HerbertDirector
- Dennis W. WahrExecutive Officer, Director
- Tom GriffinExecutive Officer
- Henry A. PlainDirector
- Jonathan RootDirector
- Michael A, CarusiDirector
- Jacques EssingerDirector
- Offering amount
- $17.3M
- Amount sold
- $15.1M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.3MraisedJan 2022 · 49 investors · Other Health CareRule 506(b)
▶$31.3MraisedJan 2022 · 49 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan RootDirector
- Yoh-Chie LuDirector
- Gary RieschelDirector
- Dennis W. WahrExecutive Officer, Director
- Robert O'HollaDirector
- Tim HerbertDirector
- Henry PlainDirector
- Michael A. CarusiDirector
- Offering amount
- $68.2M
- Amount sold
- $31.3M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedFeb 2019 · 20 investors · Other Health CareRule 506(b)
▶$25MraisedFeb 2019 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan RootDirector
- Christopher ShenDirector
- Alexander SchmitzDirector
- Michael A. CarusiDirector
- Dennis W. WahrExecutive Officer, Director
- Carolyn NgDirector
- Henry PlainDirector
- Offering amount
- $75M
- Amount sold
- $25M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedMay 2018 · 9 investors · Other Health CareRule 506(b)
▶$4MraisedMay 2018 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kirk NielsenDirector
- Dave StassenDirector
- Mark DeemDirector
- Dennis W. WahrExecutive Officer, Director
- Hank PlainDirector
- Mike CarusiDirector
- James Lee Tze WeiDirector
- Offering amount
- $8M
- Amount sold
- $4M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42MraisedApr 2014 · 9 investors · Other Health CareRule 506(b)
▶$42MraisedApr 2014 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Hank PlainDirector
- Dennis WahrExecutive Officer, Director
- Lincoln CheeDirector
- Dave StassenDirector
- Mark DeemDirector
- Mike CarusiDirector
- Kirk NielsenDirector
- Offering amount
- $42M
- Amount sold
- $42M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Nuvaira went on to found or lead other companies.
Related companies · 7
QnoviaQnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Supira MedicalSupira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock. It is a cardiovascular medical device company formed by the Shifamed innovation hub.
CqmedicalCQ Medical develops patient positioning and immobilization products used in radiation therapy, including devices for brachytherapy, SBRT, SRS, and proton treatments. Its offerings serve oncology and radiotherapy clinicians treating cancer and conditions such as osteoarthritis.
Insightra MedicalInsightra Medical develops intra-aortic balloon pump (IABP) catheters used to temporarily support heart function, including a 7Fr IAB catheter kit compatible with Arrow and Datascope consoles. The products are FDA-cleared medical devices intended for use by medical professionals in cardiac catheterization settings.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Pacira NASDAQ: PCRX www.pacira.comPacira develops and commercializes non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, and is advancing a gene therapy pipeline candidate. It serves patients and healthcare providers seeking alternatives to opioid pain management.
Companies working in the same space as Nuvaira.
In the news
Frequently asked questions
- What does Nuvaira do?
- Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD). The treatment targets COPD patients with lung hyperinflation and low emphysema, aiming to preserve lung function, reduce breathlessness, and lower exacerbations.
- Who founded Nuvaira?
- Nuvaira was founded by Martin Mayse, Steve Dimmer in 2008.
- Who are Nuvaira's investors?
- Nuvaira's investors include Windham Capital Partners, Endeavour Vision, Lightstone Ventures, Morgenthaler, Qiming Venture Partners, Richard King Mellon Foundation, Split Rock Partners, U.S. Venture Partners and 1 more.
- How much funding has Nuvaira raised?
- Nuvaira has disclosed $154.3M raised across 8 rounds.
- Where is Nuvaira headquartered?
- Nuvaira is headquartered in Minneapolis, US.